HyQvia

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

资料单张 资料单张 (PIL)
08-03-2024
产品特点 产品特点 (SPC)
08-03-2024
公众评估报告 公众评估报告 (PAR)
16-08-2016

有效成分:

Human normal immunoglobulin

可用日期:

Baxalta Innovations GmbH

ATC代码:

J06BA01

INN(国际名称):

human normal immunoglobulin

治疗组:

Immune sera and immunoglobulins,

治疗领域:

Immunologic Deficiency Syndromes

疗效迹象:

Replacement therapy in adults, children and adolescents (0-18 years) in:Primary immunodeficiency syndromes with impaired antibody production.Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia (CLL), in whom prophylactic antibiotics have failed or are contra‑indicated.Hypogammaglobulinaemia and recurrent bacterial infections in multiple myeloma (MM) patients.Hypogammaglobulinaemia in patients pre‑ and post‑allogeneic hematopoietic stem cell transplantation (HSCT).

產品總結:

Revision: 20

授权状态:

Authorised

授权日期:

2013-05-16

资料单张

                                35
B. PACKAGE LEAFLET
36
PACKAGE LEAFLET: INFORMATION FOR THE USER
HYQVIA 100 MG/ML SOLUTION FOR INFUSION FOR SUBCUTANEOUS USE
HUMAN NORMAL IMMUNOGLOBULIN
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What HyQvia is and what it is used for
2.
What you need to know before you use HyQvia
3.
How to use HyQvia
4.
Possible side effects
5.
How to store HyQvia
6.
Contents of the pack and other information
1.
WHAT HYQVIA IS AND WHAT IT IS USED FOR
WHAT HYQVIA IS
HyQvia contains 2 solutions for infusion (drip) under the skin
(subcutaneous or SC infusion).
It is supplied as a package containing:
•
one vial of human normal immunoglobulin 10% (the active substance)
•
one vial of recombinant human hyaluronidase (a substance which helps
the human normal
immunoglobulin 10% reach your blood).
Human normal immunoglobulin 10% belong to a class of medicines called
“human normal
immunoglobulins”. Immunoglobulins are also known as antibodies and
are found in healthy people’s
blood. Antibodies are part of the immune system (the body’s natural
defences) and help your body to
fight infections.
HOW HYQVIA WORKS
The recombinant human hyaluronidase is a protein that makes it easier
for the immunoglobulins to be
infused (dripped) under the skin and to reach your blood system.
The vial of immunoglobulins has been prepared from the blood of
healthy people. Immunoglobulins
are produced by the human body’s immune system. They help your body
to fight infections caused by
bacteria and viruses or maintain 
                                
                                阅读完整的文件
                                
                            

产品特点

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
HyQvia 100 mg/mL solution for infusion for subcutaneous use
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
HyQvia is a dual vial unit consisting of one vial of human normal
immunoglobulin
(Immune Globulin 10% or IG 10%) and one vial of recombinant human
hyaluronidase (rHuPH20).
Human normal immunoglobulin (SCIg)*
One mL contains:
Human normal immunoglobulin.
100 mg
(purity of at least 98% IgG)
Each vial of 25 mL contains: 2.5 g of human normal immunoglobulin
Each vial of 50 mL contains: 5 g of human normal immunoglobulin
Each vial of 100 mL contains: 10 g of human normal immunoglobulin
Each vial of 200 mL contains: 20 g of human normal immunoglobulin
Each vial of 300 mL contains: 30 g of human normal immunoglobulin
Distribution of the IgG subclasses (approx. values):
IgG
1
≥ 56.9%
IgG
2
≥ 26.6%
IgG
3
≥ 3.4%
IgG
4
≥ 1.7%
The maximum IgA content is 140 micrograms/mL.
*Produced from the plasma of human donors.
Recombinant human hyaluronidase (rHuPH20)
One mL contains:
Recombinant human hyaluronidase.
160 units
Each vial of 1.25 mL contains: 200 units of recombinant human
hyaluronidase
Each vial of 2.5 mL contains: 400 units of recombinant human
hyaluronidase
Each vial of 5 mL contains: 800 units of recombinant human
hyaluronidase
Each vial of 10 mL contains: 1600 units of recombinant human
hyaluronidase
Each vial of 15 mL contains: 2400 units of recombinant human
hyaluronidase
Excipients with known effects:
•
Recombinant human hyaluronidase (rHuPH20)
The rHuPH20is a purified glycoprotein of 447 amino acids produced in
Chinese Hamster Ovary
(CHO) cells by recombinant DNA technology
•
Sodium (as chloride and as phosphate)
The total sodium content of recombinant human hyaluronidase is 4.03
mg/mL.
For the full list of excipients, see section 6.1.
3
3.
PHARMACEUTICAL FORM
Solution for infusion.
IG 10% is a clear or slightly opalescent and colourless or pale-yellow
solution. The solution has a
pH of 4.6 to 5.1 and an osmolality of 240
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 08-03-2024
产品特点 产品特点 保加利亚文 08-03-2024
公众评估报告 公众评估报告 保加利亚文 16-08-2016
资料单张 资料单张 西班牙文 08-03-2024
产品特点 产品特点 西班牙文 08-03-2024
公众评估报告 公众评估报告 西班牙文 16-08-2016
资料单张 资料单张 捷克文 08-03-2024
产品特点 产品特点 捷克文 08-03-2024
公众评估报告 公众评估报告 捷克文 16-08-2016
资料单张 资料单张 丹麦文 08-03-2024
产品特点 产品特点 丹麦文 08-03-2024
公众评估报告 公众评估报告 丹麦文 16-08-2016
资料单张 资料单张 德文 08-03-2024
产品特点 产品特点 德文 08-03-2024
公众评估报告 公众评估报告 德文 16-08-2016
资料单张 资料单张 爱沙尼亚文 08-03-2024
产品特点 产品特点 爱沙尼亚文 08-03-2024
公众评估报告 公众评估报告 爱沙尼亚文 16-08-2016
资料单张 资料单张 希腊文 08-03-2024
产品特点 产品特点 希腊文 08-03-2024
公众评估报告 公众评估报告 希腊文 16-08-2016
资料单张 资料单张 法文 08-03-2024
产品特点 产品特点 法文 08-03-2024
公众评估报告 公众评估报告 法文 16-08-2016
资料单张 资料单张 意大利文 08-03-2024
产品特点 产品特点 意大利文 08-03-2024
公众评估报告 公众评估报告 意大利文 16-08-2016
资料单张 资料单张 拉脱维亚文 08-03-2024
产品特点 产品特点 拉脱维亚文 08-03-2024
公众评估报告 公众评估报告 拉脱维亚文 16-08-2016
资料单张 资料单张 立陶宛文 08-03-2024
产品特点 产品特点 立陶宛文 08-03-2024
公众评估报告 公众评估报告 立陶宛文 16-08-2016
资料单张 资料单张 匈牙利文 08-03-2024
产品特点 产品特点 匈牙利文 08-03-2024
公众评估报告 公众评估报告 匈牙利文 16-08-2016
资料单张 资料单张 马耳他文 08-03-2024
产品特点 产品特点 马耳他文 08-03-2024
公众评估报告 公众评估报告 马耳他文 16-08-2016
资料单张 资料单张 荷兰文 08-03-2024
产品特点 产品特点 荷兰文 08-03-2024
公众评估报告 公众评估报告 荷兰文 16-08-2016
资料单张 资料单张 波兰文 08-03-2024
产品特点 产品特点 波兰文 08-03-2024
公众评估报告 公众评估报告 波兰文 16-08-2016
资料单张 资料单张 葡萄牙文 08-03-2024
产品特点 产品特点 葡萄牙文 08-03-2024
公众评估报告 公众评估报告 葡萄牙文 16-08-2016
资料单张 资料单张 罗马尼亚文 08-03-2024
产品特点 产品特点 罗马尼亚文 08-03-2024
公众评估报告 公众评估报告 罗马尼亚文 16-08-2016
资料单张 资料单张 斯洛伐克文 08-03-2024
产品特点 产品特点 斯洛伐克文 08-03-2024
公众评估报告 公众评估报告 斯洛伐克文 16-08-2016
资料单张 资料单张 斯洛文尼亚文 08-03-2024
产品特点 产品特点 斯洛文尼亚文 08-03-2024
公众评估报告 公众评估报告 斯洛文尼亚文 16-08-2016
资料单张 资料单张 芬兰文 08-03-2024
产品特点 产品特点 芬兰文 08-03-2024
公众评估报告 公众评估报告 芬兰文 16-08-2016
资料单张 资料单张 瑞典文 08-03-2024
产品特点 产品特点 瑞典文 08-03-2024
公众评估报告 公众评估报告 瑞典文 16-08-2016
资料单张 资料单张 挪威文 08-03-2024
产品特点 产品特点 挪威文 08-03-2024
资料单张 资料单张 冰岛文 08-03-2024
产品特点 产品特点 冰岛文 08-03-2024
资料单张 资料单张 克罗地亚文 08-03-2024
产品特点 产品特点 克罗地亚文 08-03-2024
公众评估报告 公众评估报告 克罗地亚文 16-08-2016

搜索与此产品相关的警报

查看文件历史